“Epstein-Barr virus and malaria co-infection may create a lethal combination,” according to a study published in PloS Pathogens. (1)

ROCHESTER, NEW YORK, UNITED STATES OF AMERICA, August 12, 2015 /EINPresswire.com/ --

“Infected with the Epstein Barr Virus (EBV)? The Center for the Biology of Chronic Disease (CBCD) recommends taking Gene-Eden-VIR or Novirin.” – Greg Bennett, CBCD

A co-infection with the Epstein-Barr Virus (EBV) and malaria can be fatal, according to a new study. In fact, researchers now believe that a co-infection with these two disease causing organisms is “one possible explanation for why young children are so much more vulnerable to severe malaria.” (1) The data backs this belief since “Almost all African children will be infected with both Epstein-Barr virus and malaria by the age of 6-12 months. Because both of these infections occur around the same time in these children, many are at a high risk for co-infection before the age of 1.” (1)

Importantly, scientists discovered that “mice recently infected with a gammaherpesvirus have a compromised immune response and that subsequent infection with Plasmodium parasites often leads to severe malarial anemia, and even death. The study presents evidence that the complications that lead to many child malaria deaths may be partially due to EBV infection.” (1)

The CDC notes that “Epstein-Barr Virus (EBV), also known as human herpesvirus 4, is a member of the herpes virus family. It is one of the most common human viruses. EBV is found all over the world. Most people get infected with EBV at some point in their lives.” (2) The Center for the Biology of Chronic Disease (CBCD) reminds the public that, while malaria is not a risk for those who live in the United States and other Western nations, EBV is still a dangerous virus. The CBCD recommends that in light of the medical evidence, infected individuals take Gene-Eden-VIR or Novirin. The formula of these natural, antiviral supplements was designed to help the immune system target the latent EBV.

Click to learn more about EBV symptoms.

The formula of Gene-Eden-VIR and Novirin was tested by Hanan Polansky and Edan Itzkovitz from the CBCD in two clinical studies that followed FDA guidelines. The studies showed that the Novirin formula is effective against the herpes family of viruses. The Epstein Barr Virus (EBV) is a member of the herpes family. The clinical studies were published in the peer reviewed, medical journal Pharmacology & Pharmacy, the first, in a special edition on Advances in Antiviral Drugs. Study authors wrote that, “individuals infected with the EBV … reported a safe decrease in their symptoms following treatment with (the formula of Novirin).” (3) The study authors also wrote that, “We observed a statistically significant decrease in the severity, duration, and frequency of symptoms.” (3)

Gene-Eden-VIR and Novirin can be ordered online on their respective websites, here:

http://www.gene-eden-vir.com

and

http://www.novirin.com

Gene-Eden-VIR and Novirin are natural antiviral dietary supplements. Their shared formula contains five natural ingredients: Selenium, Camellia Sinesis Extract, Quercetin, Cinnamomum Extract, and Licorice Extract. The first ingredient is a trace element, and the other four are plant extracts. Each ingredient and its dose was chosen through a scientific approach. Scientists at polyDNA, the company that invented and patented the formula, scanned thousands of scientific and medical papers published in various medical and scientific journals, and identified the safest and most effective natural ingredients against latent viruses. To date, Gene-Eden-VIR and Novirin are the only natural antiviral products on the market with published clinical studies that support their claims.

Note: Novirin has the same formula as Gene-Eden-VIR. However, it contains higher quality and more expensive ingredients.

In the study mentioned above, researchers discovered that “acute EBV infection suppresses the humoral immune response, which works through the production of antibodies. The humoral immune response is also important in fighting malaria. The researchers found that when a Plasmodium infection occurs during an acute gammaherpesvirus infection, the gammaherpesvirus weakens the immune response to Plasmodium and the (individual) is likely to develop severe malaria. How this works remains unknown.” (1)

What treatments are available for EBV infections?

“A few antiviral drugs are available that were shown to inhibit EBV replication in cell culture. These drugs include the acyclic nucleoside analogues aciclovir, ganciclovir, penciclovir, and their respective prodrugs valaciclovir, valganciclovir and famciclovir, the acyclic nucleotide analogues cidofovir and adefovir, and the pyrophosphate analogue foscarnet. However, clinical studies have shown that these drugs are mostly ineffective in humans.” (3) There are also natural antiviral products that studies show to be safe and effective in reducing EBV symptoms. Two of these products are Gene-Eden-VIR and Novirin.

“Based on the results of these studies, and the CBCD’s own research, we recommend that EBV infected individuals take Gene-Eden-VIR or Novirin.” - Greg Bennett, CBCD

The CBCD reminds the public that Gene-Eden-VIR and Novirin are not a cure. However, two clinical studies showed that their formula decreases symptoms in infected individuals. Specifically, the formula of Gene-Eden-VIR and Novirin was shown to safely and effectively reduce EBV symptoms. Additionally, it was designed to help the immune system target the latent virus.

All orders of these products are completely confidential, and no information is shared or sold to any third party. Privacy is assured.

References:

(1) PLoS Pathogens - "Malaria and Epstein-Barr Virus: A Lethal Combination" Published on May 21, 2015 – plos.org

(2) CDC.com - About Epstein-Barr Virus (EBV). Last updated January 6, 2014.

(3) Polansky, H. Itzkovitz, E. Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Published in September 2013.
http://www.scirp.org/journal/PaperInformation.aspx?PaperID=36101

Greg Bennett
CBCD
585-250-9999
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.